These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38172379)

  • 1. Pediatric Market Access: A Qualitative Study.
    Maas L; Joos A; Hiligsmann M
    Ther Innov Regul Sci; 2024 Mar; 58(2):336-346. PubMed ID: 38172379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
    Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
    Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
    Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A David and Goliath set-up: a qualitative study of the challenges of ensuring the introduction of cost-effective new cancer medicines in Finland.
    Ollila E; Kataja V; Sailas L
    J Pharm Policy Pract; 2022 Aug; 15(1):52. PubMed ID: 36038900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
    Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
    [No Abstract]   [Full Text] [Related]  

  • 7. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
    Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
    Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of drug regulatory authorities and health technology assessment agencies in shaping incentives for antibiotic R&D: a qualitative study.
    Kållberg C; Mathiesen L; Gopinathan U; Salvesen Blix H
    J Pharm Policy Pract; 2023 Mar; 16(1):53. PubMed ID: 36973761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
    Mahalatchimy A
    Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs-Can Alignment Be Enhanced?
    Wolters S; Jansman FGA; Postma MJ
    Value Health; 2022 Dec; 25(12):1958-1966. PubMed ID: 35752535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 13. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries.
    Post HC; Schutte T; van Oijen MGH; van Laarhoven HWM; Hollak CEM
    ESMO Open; 2023 Apr; 8(2):101208. PubMed ID: 37030113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
    Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
    J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing access to orphan medicinal products in Europe.
    Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
    Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Market access pathways for cell therapies in France.
    Rémuzat C; Toumi M; Jørgensen J; Kefalas P
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.